Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Once a broad tumor class is established, more specific differentiation markers can be pursued (e.g., lineage-restricted transcription factors for adenocarcinoma; p40 for squamous cell carcinoma; chromogranin A and synaptophysin or INSM1 for neuroendocrine neoplasms).
|
31786484 |
2020 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Once a broad tumor class is established, more specific differentiation markers can be pursued (e.g., lineage-restricted transcription factors for adenocarcinoma; p40 for squamous cell carcinoma; chromogranin A and synaptophysin or INSM1 for neuroendocrine neoplasms).
|
31786484 |
2020 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab (UST) is an antibody to the p40 subunit of interleukins 12 and 23 in Crohn's disease (CD) patients.
|
31722356 |
2020 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Once a broad tumor class is established, more specific differentiation markers can be pursued (e.g., lineage-restricted transcription factors for adenocarcinoma; p40 for squamous cell carcinoma; chromogranin A and synaptophysin or INSM1 for neuroendocrine neoplasms).
|
31786484 |
2020 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
TTF-1 and napsin A IHC stainings had similar specificity but better sensitivity for adenocarcinoma than the mucin stains, but addition of PASD or ABPAS identified more tumors as adenocarcinomas (n = 8 and n = 10, respectively) than napsin A (n = 1) in cases with solid growth that were negative for TTF-1 and p40.
|
30718697 |
2019 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Utility of p63 and p40 in Distinguishing Polymorphous Adenocarcinoma and Adenoid Cystic Carcinoma.
|
31653135 |
2019 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although P40 staining for the sarcomatous component was positive along with squamous carcinoma, E-cadherin expression disappeared while vimentin was expressed.
|
31366562 |
2019 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both lesions were squamous cell carcinoma and positive for p40.
|
31845086 |
2019 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The monoclonal antibody targeting the shared p40 subunit of IL-12 and IL23, namely ustekinumab, has been approved for Crohn's disease (CD) and has demonstrated promising results in the treatment of ulcerative colitis.
|
30884245 |
2019 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The approval of ustekinumab, a monoclonal antibody blocking the common p40 subunit of IL12 and IL23, marked an important evolution in medical management for CD: this novel class of biologic therapy demonstrated efficacy in both patients naïve to biologics as well as in patients experiencing inadequate response or loss of response to TNF antagonists.
|
31327402 |
2019 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab and briakinumab are monoclonal antibodies that target the standard p40 subunit of cytokines interleukin-12 and interleukin-23 (IL-12/23p40), which are involved in the pathogenesis of Crohn's disease (CD).
|
31828765 |
2019 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Consistently, neutralizing antibodies against IL-12/IL-23 p40 and IL-23 p19 have been successfully used in clinical trials for therapy of Crohn´s disease and pilot studies in ulcerative colitis are ongoing.
|
30563755 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The selected markers included CK5/6, p40, CK19, BerEP4, p16 and SOX10.All tumors were CK5/6 and p40 positive.
|
31548087 |
2019 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Adamantinoma-like Ewing sarcoma (ALES) is a rare tumor that demonstrates the EWSR1-FLI1 translocation characteristic of Ewing sarcoma despite overt epithelial differentiation including diffuse expression of cytokeratins and p40.
|
30285997 |
2019 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As tumor cells showed positive immunostaining for p40 and CK5/6, the immunophenotype of the tumor was consistent with squamous cell carcinoma (SCC).
|
30216599 |
2018 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytokeratin 5/6 (CK5/6), p63, and p40 are commonly used as immunohistochemical markers for squamous cell carcinoma (SqCC) of the lung.
|
30546464 |
2018 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lastly, ustekinumab, a monoclonal antibody (mAb) to the p40 subunit of IL-12 and IL-23, has showed good efficacy and safety profile in patients with Crohn's disease (CD).
|
30060945 |
2018 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab is a monoclonal antibody that binds with high affinity to the p40 subunit of human interleukin 12 (IL12 and IL23) that has been approved for treatment of patients with moderate to severe Crohn's disease (CD).
|
29409871 |
2018 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab is an interleukin inhibitor which blocks the p40 subunit of IL-12 and IL-23 axis and is already approved for the treatment of Crohn's disease patients, specially those who had inadequate response or intolerance to conventional treatment with anti-TNF-α agents.
|
29846261 |
2018 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
The introduction of ustekinumab, an interleukin [IL]12/23 p40 inhibitor, to the therapeutic armamentarium of Crohn's disease has provided a much needed treatment option for patients who have failed conventional biologics with anti-tumour necrosis factor [TNF] and anti-integrin agents.
|
30169620 |
2018 |
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the ability of ustekinumab, a monoclonal antibody against the p40 subunit of interleukins 12 and 23, to induce endoscopic healing in patients with moderate to severe Crohn's disease (CD).
|
29909019 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
As tumor cells showed positive immunostaining for p40 and CK5/6, the immunophenotype of the tumor was consistent with squamous cell carcinoma (SCC).
|
30216599 |
2018 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We evaluated expression of Sox10 and DOG1 in normal cutaneous adnexa and in 194 primary skin adnexal tumors, and compared their performance in discriminating primary skin adnexal tumors from cutaneous metastatic adenocarcinomas with that of p40 and p63.
|
28394798 |
2017 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We characterized captured cells using TTF1 and p40 as immunostaining biomarkers of adenocarcinoma and squamous cell carcinoma, respectively.
|
28298147 |
2017 |
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Polyclonal p40 yields a level of false positivity in ACAs similar to p63, which is highest in effusions and is not limited to lung origin.
|
28498881 |
2017 |